Nucleus Network has acquired UK-based Hammersmith Medicines Research (HMR), a move that establishes the company as the only early-phase clinical trial provider with dedicated facilities in Australia, the United States and the United Kingdom.

The acquisition strengthens Nucleus Network’s position as a global leader in early-phase research and reflects a shared mission between the two organisations to advance medicine and improve lives. It also honours the legacy of Dr Malcolm Boyce, who led HMR to become a centre of excellence in early-phase trials across the UK and Europe.

“We are deeply honoured by the trust Dr Boyce has placed in us to carry forward HMR’s legacy,” said Teena Pisarev, chief executive officer of Nucleus Network. “This acquisition is about more than expanding our global footprint. It reflects a genuine alignment of values, culture and purpose. Together, we are building a platform that will help redefine the way early-phase trials are delivered.”

Establishing a new global standard

With HMR now part of its network, Nucleus Network offers an integrated model that combines global reach with local clinical and regulatory expertise. The company says its multi-jurisdictional business development team will work closely with sponsors to align trial delivery with strategic priorities across regions. Studies can begin in one regulatory setting and transition to another, supported by harmonised processes and shared standards designed to reduce operational risk and accelerate timelines.

The expanded footprint will improve access to broader and more diverse volunteer and patient populations. This will support more inclusive trial designs and faster recruitment – both essential for first-in-human and adaptive studies.

HMR’s scientific and operational experience complements Nucleus Network’s digital capabilities and infrastructure. Together, the two teams aim to improve execution precision and data quality across all trial sites.

According to the company, sponsors will benefit from a more streamlined process, with unified systems and coordinated project delivery simplifying early-phase trial complexity. The deal enhances Nucleus Network’s position as a dedicated global early-phase provider, while maintaining its partnerships with CROs worldwide.

“This acquisition expands what’s possible for our sponsors,” Pisarev added. “It deepens our scientific capabilities, strengthens our operational reach and reinforces our commitment to delivering life-changing therapies to patients around the world.”

Nucleus Network will continue to operate its clinical sites in Brisbane, Melbourne and Sydney (from 2026), Australia; Minneapolis, Minnesota; and London, UK, maintaining continuity for ongoing studies and trusted sponsor relationships.